Efruxifermin Publications

Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH

Frias, J. et al. (2021) ADA Scientific Sessions

Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin

Harrison, S. et al. (2021) EASL

The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial

Loomba, R. et al. (2021) EASL

LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice

Le CT et al. (2018) PLOS ONE

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Sanyal A et al. (2018) Lancet

A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway

Bao L et al. (2018) British J Pharmacol

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys

Stanislaus S et al. (2017) Endocrinol

Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway

Yu Y et al. (2016) Int. Immunopharmacol

Fibroblast Growth Factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets

Fisher FM et al. (2014) Gastroenterology

Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions

Ge, H et al. (2014) J Biol Chem

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects

Xu et al. (2009) Am J Physiol Endocrinol Metab

Fibroblast Growth Factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

Xu J et al. (2009) Diabetes